Welcome to our dedicated page for Moleculin Biotec news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotec stock.
Moleculin Biotech, Inc. reports developments as a clinical-stage pharmaceutical company advancing drug candidates for hard-to-treat tumors and viruses. Its lead program is Annamycin, also known as naxtarubicin, a next-generation anthracycline designed to avoid cardiotoxicity and multidrug resistance, with development focused on relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Recurring news covers Annamycin clinical and preclinical data, the MIRACLE study of Annamycin in combination with cytarabine, oncology conference presentations, intellectual-property protection for liposomal Annamycin, and corporate financial updates. Additional pipeline coverage includes WP1066, an immune/transcription modulator targeting p-STAT3 and other oncogenic transcription factors, and WP1122, an antimetabolite program for pathogenic viruses and cancer indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Moleculin Biotech, Inc. (Nasdaq: MBRX) presented positive preclinical data for Annamycin, a next-generation anthracycline, at the American Association for Cancer Research (AACR) Annual Meeting 2023. The research showcased Annamycin's enhanced liver accumulation, significantly exceeding doxorubicin's uptake, and demonstrated high antitumor efficacy in liver cancer models. Key findings included a six-fold increase in liver accumulation compared to doxorubicin, substantial inhibition of tumor growth, and improved survival rates in various models. Annamycin is currently under evaluation in clinical trials targeting soft tissue sarcoma lung metastases and acute myeloid leukemia. These promising results bolster future studies and potential for Annamycin as a viable treatment option for hard-to-treat tumors.
Moleculin Biotech (NASDAQ: MBRX) reported its financial results for 2022, showing a net loss of $29.0 million, up from $6.7 million in 2021. R&D expenses increased to $19.0 million, driven by heightened clinical trial activities. The company has sufficient cash, totaling $43.1 million, to fund operations into the third quarter of 2024. Recent highlights include positive data from Annamycin's trials, an 80% overall response rate for refractory AML, and Fast Track Designation from the FDA for WP1122. A conference call to discuss results will be held on March 23, 2023, at 8:30 AM ET.
Moleculin Biotech, Inc. (MBRX) announced significant updates regarding its clinical trials on March 22, 2023. The company is actively recruiting for three Phase 1b/2 trials, with one trial having recently transitioned to Phase 2. Notably, Moleculin has achieved 50% recruitment in its Phase 2 trial targeting soft tissue sarcoma (STS) lung metastases. Preliminary results from the trials indicate a 67% response rate and no cardiotoxicity associated with its lead drug, Annamycin. The company anticipates multiple data readouts and milestones throughout 2023 as it advances its pipeline for hard-to-treat cancers.
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its abstract for the next-generation anthracycline, Annamycin, has been accepted for presentation at the AACR Annual Meeting 2023 from April 14-19, 2023 in Orlando, FL. The presentation, titled Exploration of Annamycin Organotropism, focuses on targeting liver cancers. Annamycin has shown potential in animal models for significantly improved localization over doxorubicin and reduced cardiotoxicity, enhancing its therapeutic prospects for treating acute myeloid leukemia and soft tissue sarcoma lung metastases.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its full year 2022 financial results on March 22, 2023, after market close. The Company is in the clinical stage, developing treatments for hard-to-treat tumors and viruses. The management will host a conference call on March 23, 2023, at 8:30 AM ET to discuss operational and financial results. Investors can access the call via phone or through a live webcast.
Moleculin Biotech, Inc. (NASDAQ: MBRX) announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:40 PM ET. Jonathan P. Foster, the Chief Financial Officer, will present a live video webcast, accessible on the Company's website. This event will also allow one-on-one meetings with registered investors. Moleculin focuses on developing treatments for hard-to-treat tumors and viruses, highlighted by its lead program Annamycin for acute myeloid leukemia and soft tissue sarcoma. The Company is also advancing several other oncology and antiviral candidates.